 Osmetech Annual Report 2004    1
Highlights
• Sales revenues well ahead of expectations at £6.2m.
• Loss before tax substantially reduced to £1.3m (2003 – £3.8m)
• Well funded Group with £3.2m in cash and term deposits at 30 April 2004
• Significant improvement in commercial and financial risk profile
• Five new OPTI products scheduled for launch in the coming year
• Good progress with development of vaginal infection product
• Important long term agreements signed with IDEXX for veterinary market
• Excellent growth prospects
